Cerevance Media Center
Current News
June 26, 2023
Cerevance to Present at the Gordon Research Conference: Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases
Cerevance today announced plans to present a poster presentation at the upcoming Gordon Research Conference: Amyotrophic Lateral Sclerosis (ALS) andRelated Motor Neuron Diseases, taking place in Les Diablerets, VD, Switzerland,July 2 – July 7, 2023.
May 16, 2023
Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Cerevance today announced plans to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
May 9, 2023
Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia,Canada, May 15 – 19, 2023.
May 8, 2023
Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare Conference
Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 2023 RBC Capital Markets Global Healthcare Conference being held May 16-17, 2023. Company management will also be available for virtual one-on-one meetings.
News Archive
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
September 5, 2023
Cerevance to Present During the 6th Annual LSX World Congress USA
Cerevance to participate in panel discussions during the 6th Annual LSX World Congress USA being held in Boston, MA, September 13-14th.
August 31, 2023
22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
Events Archive
May 30, 2023

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, & W9 Pharmacokinetic Study of Escalating Single & Multiple Doses of CVN766, an OX1R Highly Selective Antagonist, in Healthy Subjects
Vitolo et al (2023) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766, an OX1R Highly Selective Antagonist in Healthy Subjects. American Society of Clinical Psychopharmacology, Miami Beach, Florida, USA.
viewMay 9, 2023

Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease Using Cerevance’s NETSseq Platform and Analysis
Giuliano Stirparo, Xiao Xu, Marina Lizio, Justin Powell, Toni Cheung, Gonca Bayraktar, Louisa Christie, Megan Roberts, Gabriella Crane, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernadino Ossola, Nicola Brice, Keith Page, Lee A. Dawson & Mark Carlton (2023) Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease using Cerevance’s NETSseq Platform and Analysis. Keystone Meeting: Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development, Whi
viewMay 2, 2023

Phase 1 Study of CVN424, a Novel GPR6 Inverse Agonist
Margolin, D.H., Brice, N.L., Davidson, A.M., Matthews, K.L., Carlton, M.B.L. (2022) Phase I, First- In-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel GPR6 Inverse Agonist for Parkinson’s Disease. J. Pharmacol. Exp. Ther. 381: 33– 41
viewApril 1, 2023

CVN424, a Novel GPR6 Inverse Agonist Demonstrates Efficacy in an Adjunctive Parkinson’s Disease Phase 2 Clinical Trial
Karl Kieburtz, David Margolin, Jordon Dubow, Kim Matthews, Roland Burli, Lee A. Dawson, Naidong Ye, Mark B Carlton, Nicola L Brice (2023) CVN424, a novel GPR6 inverse agonist demonstrates efficacy in an adjunctive Parkinson’s Disease phase 2 clinical trial. Int Conf Alzheimer’s & Parkinson’s Diseases & related neurological disorders, Gothenburg, Sweden
viewMarch 31, 2023

NETSseq Reveals Deep Molecular Insights Into Alzheimer’s and Parkinson’s Disease and Facilitates Identification of Novel Therapeutic Targets
Xiao Xu, Giuliano Stirparo, Marina Lizio, Justin Powell, Toni Cheung, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernadino Ossola, Nicola Brice, Keith Page, Lee A. Dawson, Mark Carlton (2023) NETSseq reveals deep molecular insights into Alzheimer’s disease progression and facilitates identification of novel therapeutic targets. Int Conf Alzheimer’s & Parkinson’s Diseases & related neurological disorders, Gothenburg, Sweden
viewMarch 1, 2023

NETSseq Provides Deep Molecular Insights into Alzheimer’s Disease Progression Enabling Selection of Novel Therapeutic Targets
Louisa Christie, Xiao Xu, Giuliano Stirparo, Marina Lizio, Justin Powell, Louise Dickson, Toni Cheung, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernardino Ossola, Nicola Brice, Keith Page, Lee A. Dawson & Mark Carlton (2023) NETSseq Provides Deep Molecular Insights Into Alzheimer’s Disease Progression Enabling Selection Of Novel Therapeutic Targets For Drug Discovery. Alzheimer’s Research UK Conference, Aberdeen, UK.
view